 |
| Image created by Dr. Michael J. Miller |
Diasorin announced today that, following the recent 510(k) clearance and CLIA-waiver from the U.S. Food and Drug Administration (FDA) for its first assay—the FLU A/B, RSV & COVID-19 Panel for use on the LIAISON NES® platform— the Company has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific, for the LIAISON NES® molecular point-of-care (POC) platform in the U.S. hospital market.
The LIAISON NES® is a next-generation molecular POC system designed to expand access to high-quality diagnostic testing in decentralized settings. Its fully automated workflow requires only a few seconds of hands-on time and delivers results in approximately 15 minutes, enabling timely clinical decisions while reducing dependence on specialized laboratory personnel.
The U.S. represents one of the largest global markets for molecular respiratory testing, with over 7,000 hospitals and approximately 130,000 POLs performing such diagnostics. Fisher Scientific’s strong footprint and established relationships across the hospital channel make it a strategic partner for the introduction and scale-up of the LIAISON NES® platform and its respiratory panel.
The agreement strengthens Diasorin’s commercial capabilities in the hospital segment, complementing the Company’s existing U.S. commercial organization, which today promotes Diasorin’s molecular solutions—including LIAISON® MDX and LIAISON® PLEX—as well as the recently expanded salesforce dedicated to the LIAISON NES® program.
“This agreement will accelerate our entry into the hospital segment and support access to major U.S. Integrated Delivery Networks (IDNs),” commented Carlo Rosa, CEO of Diasorin.
“We are also working to finalize additional distribution agreements with others in the United States aimed at providing full coverage of the non-acute market segment, which includes more than 130,000 POLs, ensuring a comprehensive and efficient go-to-market strategy across all key customer categories”.